Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | PNP | P00491 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 4/20 | 0.40 |
| ▸ | PI4KA | P42356 | 6/20 | 0.38 |
| ▸ | PI4K2B | Q8TCG2 | 6/20 | 0.38 |
| ▸ | PI4K2A | Q9BTU6 | 6/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 6/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2639251 | 0.79 | ADORA2A (0.37) | ADORA2AADORA1ALDH1A1NUDT1PI4KA | |
| SCHEMBL42314 | 0.79 | ADORA2A (0.66) | ADORA2AADORA1ALDH1A1NUDT1PI4KA | |
| SCHEMBL8906323 | 0.78 | AKT2 (0.44) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL6831171 | 0.76 | ADORA2A (0.52) | ADORA2AADORA1PNPKDM4EMEN1 | |
| SCHEMBL932299 | 0.76 | ADORA2A (0.35) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL5490464 | 0.76 | KDM4E (0.44) | ADORA2AADORA1PNPKDM4EMEN1 | |
| SCHEMBL94915 | 0.76 | ADORA2A (0.35) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL320848 | 0.76 | NUDT1 (0.43) | ADORA2AADORA1PNPKDM4EMEN1 | |
| SCHEMBL931970 | 0.76 | ADORA2A (0.61) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL9010833 | 0.76 | ADORA2A (0.35) | ADORA2AADORA1NUDT1PI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1507873-A4 | PARALLEL STRANDED DUPLEXES OF DEOXYRIBONUCLEIC ACID AND METHODS OF USE | CYGENE INC (US) | 2006-12-27 | — | — | EP | claimed |
| EP-1730158-A2 | METHODS AND COMPOSITIONS FOR IN VITRO AND IN VIVO USE OF PARALLEL STRANDED HAIRPINS AND TRIPLEX STRUCTURES AS NUCLEIC ACID LIGANDS | Cygene, Inc. (US) | 2006-12-13 | — | — | EP | claimed |
| US-20060008813-A1 | Compositions and methods of synthesis and use of novel nucleic acid structures | ERITJA RAMON | 2006-01-12 | — | — | US | claimed |
| US-20050197305-A1 | Methods and compositions for blocking progression of a disease state | LOPEZ MARTIN J (CA) | 2005-09-08 | — | — | US | claimed |
| WO-2005067437-A2 | METHODS AND COMPOSITIONS FOR IN VITRO AND IN VIVO USE OF PARALLEL STRANDED HAIRPINS AND TRIPLEX STRUCTURES AS NUCLEIC ACID LIGANDS | CYGENE, INC. (US) | 2005-07-28 | — | — | WO | claimed |
| US-20050089893-A1 | Methods and compositions for in vitro and in vivo use of parallel stranded hairpins and triplex structures as nucleic acid ligands | CYGENE, INC. | 2005-04-28 | — | — | US | claimed |
| WO-2005025495-A2 | METHODS AND COMPOSITIONS FOR BLOCKING PROGRESSION OF A DISEASE STATE | CYGENE LABORATORIES, INC. (US) | 2005-03-24 | — | — | WO | claimed |
| EP-1507873-A1 | PARALLEL STRANDED DUPLEXES OF DEOXYRIBONUCLEIC ACID AND METHODS OF USE | Cygene, Inc. (US) | 2005-02-23 | — | — | EP | claimed |
| US-20050014164-A1 | Triplex-forming oligonucleotides containing modified purines and their applications | ERITJA RAMON (ES) | 2005-01-20 | — | — | US | claimed |
| WO-2004037981-A2 | TRIPLEX-FORMING OLIGONUCLEOTIDES CONTAINING MODIFIED PURINES AND THEIR APPLICATIONS | CYGENE LABORATORIES, INC. (US) | 2004-05-06 | — | — | WO | claimed |
| US-20040029160-A1 | Parallel stranded duplexes of deoxyribonucleic acid and methods of use | CYGENE, INC. | 2004-02-12 | — | — | US | claimed |
| WO-2003100099-A1 | PARALLEL STRANDED DUPLEXES OF DEOXYRIBONUCLEIC ACID AND METHODS OF USE | CYGENE, INC. (US) | 2003-12-04 | — | — | WO | claimed |
| US-20250127787-A1 | METHODS FOR TREATING PERIPHERAL NEUROPATHY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-04-24 | — | — | US | disclosed |
| EP-4408531-A1 | METHODS FOR TREATING PERIPHERAL NEUROPATHY | University of Pittsburgh - of the Commonwealth System of Higher Education (US) | 2024-08-07 | — | — | EP | disclosed |
| WO-2023055531-A1 | METHODS FOR TREATING PERIPHERAL NEUROPATHY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20230089949-A1 | SMALL MOLECULES FOR TREATING AGE-RELATED RETINAL DISEASES | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-03-23 | — | — | US | disclosed |
| WO-2001032924-A1 | COMPOSITIONS AND METHODS OF SYNTHESIS AND USE OF NOVEL NUCLEIC ACID STRUCTURES | CYGENE, INC. (US) | 2001-05-10 | — | — | WO | disclosed |
| EP-0034038-B1 | USE OF SILVER HALIDE DEVELOPMENT ACCELERATORS, PHOTOGRAPHIC FILMS AND PROCESSES FOR DEVELOPING LITHOGRAFIC FILM | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-05-30 | — | — | EP | disclosed |
| US-4292391-A | PYRAZOLO/3,4-D/PYRIMIDINES; PHOTOLITHOGRAPHY | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-09-29 | — | — | US | disclosed |
| EP-0034038-A1 | Use of silver halide development accelerators, photographic films and processes for developing lithografic film | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089949-A1 | SMALL MOLECULES FOR TREATING AGE-RELATED RETINAL DISEASES | PNP, PDE6B, PDE6A | ADORA2A 209/4885ADORA1 465/4885PNP 1/4885 |
| US-20250127787-A1 | METHODS FOR TREATING PERIPHERAL NEUROPATHY | PNP, PNPO, PRPH | ADORA2A 589/4885ADORA1 1006/4885PNP 1/4885 |
| US-20040029160-A1 | Parallel stranded duplexes of deoxyribonucleic acid and methods of use | DDX18, DDX1, ADAR | ADORA2A 250/4885ADORA1 341/4885PNP 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.